Source disclosure: February 02, 2026
SymBio Pharmaceuticals Limited [4582.T]
TOKYO, Feb 02 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) signed a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health's National Institute of Neurological Disorders and Stroke (NINDS).
The pact aims to conduct a pilot clinical trial of IV BCV for Progressive Multifocal Leukoencephalopathy (PML), a rare and life-threatening brain disease. The trial, led by Dr. Irene Cortese at NINDS' Immunotherapy Research Unit, will involve 18 PML patients at the NIH Clinical Center in Bethesda, Maryland.
Previous preclinical studies by Penn State College of Medicine’s Aron Lukacher lab suggested IV BCV's high antiviral activity against polyomaviruses, including JC virus. The goal is to evaluate IV BCV's efficacy and safety in PML patients. Commenting on the agreement, CEO Fumiki Yoshida said, “We are proud to collaborate with NIH/NINDS on pioneering treatments for untreatable diseases like PML.
This aligns with our strategy to expand BCV development across three therapeutic areas.” The deal marks SymBio's third CRADA with NIH and is expected to contribute to future regulatory filings and further clinical development without impacting the fiscal year ending December 2026 forecasts.
AI-translated content. 🟢 Confidence: High See terms • Original filing